Vanguard Group Inc Compass Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,283,186 shares of CMPX stock, worth $5.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,283,186

Previous 4,192,529 2.16%

Holding current value

$5.87 Million

Previous $4.19 Million 88.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$0.8 - $1.88 $72,525 - $170,435	90,657 Added 2.16%	4,283,186 $7.88 Million
Q2 2024 Aug 13, 2024	BUY	$1.0 - $1.85 $40,332 - $74,614	40,332 Added 0.97%	4,192,529 $4.19 Million
Q1 2024 May 10, 2024	BUY	$1.2 - $2.29 $85,209 - $162,608	71,008 Added 1.74%	4,152,197 $8.22 Million
Q4 2023 Feb 14, 2024	SELL	$1.4 - $1.98 $36,862 - $52,133	-26,330 Reduced 0.64%	4,081,189 $6.37 Million
Q3 2023 Nov 14, 2023	BUY	$1.87 - $3.25 $18,021 - $31,320	9,637 Added 0.24%	4,107,519 $8.09 Million
Q2 2023 Aug 14, 2023	BUY	$2.64 - $3.48 $1.08 Million - $1.42 Million	408,556 Added 11.07%	4,097,882 $13 Million
Q1 2023 May 15, 2023	BUY	$3.14 - $5.48 $247,815 - $432,492	78,922 Added 2.19%	3,689,326 $12.1 Million
Q4 2022 Feb 10, 2023	BUY	$2.55 - $5.41 $3.14 Million - $6.65 Million	1,229,781 Added 51.66%	3,610,404 $18.2 Million
Q3 2022 Nov 14, 2022	BUY	$1.9 - $3.37 $1.67 Million - $2.96 Million	878,650 Added 58.5%	2,380,623 $5.43 Million
Q2 2022 Aug 12, 2022	SELL	$1.43 - $3.1 $101,399 - $219,817	-70,909 Reduced 4.51%	1,501,973 $3.98 Million
Q4 2021 Feb 14, 2022	BUY	$2.88 - $3.98 $4.53 Million - $6.26 Million	1,572,882 New	1,572,882 $4.99 Million

Others Institutions Holding CMPX

# of Institutions

Shares Held

91.9M

Call Options Held

Put Options Held

View Full List

About Compass Therapeutics, Inc.

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $139M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

More about CMPX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Compass Therapeutics, Inc. Transaction History